öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º»ÆéÅÁˆ
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º38

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£ºµÚÒ»ÁÙ´²Ñ§Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º
Ñо¿ÁìÓò£º ¹ÚÐIJ¡½éÈëÖÎÁÆÁÙ´²Óë»ù´¡Ñо¿¡¢ÁÙ´²¹²Í¬¾ö²ßÑо¿¡¢¶¯ÂöÖàÑùÓ²»¯»ù´¡Ñо¿¡¢¸Éϸ°ûÒÆÖ²µÄ»ù´¡ÓëÁÙ... [Õ¹¿ª]


Ñо¿ÁìÓò£º ¹ÚÐIJ¡½éÈëÖÎÁÆÁÙ´²Óë»ù´¡Ñо¿¡¢ÁÙ´²¹²Í¬¾ö²ßÑо¿¡¢¶¯ÂöÖàÑùÓ²»¯»ù´¡Ñо¿¡¢¸Éϸ°ûÒÆÖ²µÄ»ù´¡ÓëÁÙ´²Ñо¿µÈ¡£ [ÊÕÆð]




ͨѶ·½Ê½ :
µç×ÓÓʼþ£ºrchuang@aliyun.com


¸öÈ˼òÊö :
»ÆéÅÁˆ£¬Ò½Ñ§²©Ê¿£¬½ÌÊÚ¡¢Ö÷ÈÎҽʦ¡¢²©Ê¿Éúµ¼Ê¦£¬ÏÖÈδóÁ¬Ò½¿Æ´óѧ¸½ÊôµÚÒ»Ò½ÔºÈý²¿ÐÄÄÚ¿ÆÖ÷ÈΡ£2007Äê±ÏÒµÓÚ¸´µ©´óѧ¸½ÊôÖÐɽҽԺ£¬»ñµÃÄÚ¿Æѧ²©Ê¿Ñ§Î»¡£1999ÄêÖÁ½ñ¾ÍÖ°ÓÚ´óÁ¬Ò½¿Æ´óѧ¸½ÊôµÚÒ»Ò½ÔºÐÄÄÚ¿Æ£¬2001ÄêÔø¸°ÃÀ¹úTheBurnham InstituteÑÐÐÞ£¬2013Äê8ÔÂÖÁ2015Äê7Ô¶à´Î¸°ÃÀ¹úMayoClinicÐÄÄڿƺÍת»¯Ò½Ñ§Ñо¿ÖÐÐÄѧϰ²¢ÊÜÑû³ÉΪÃÀ¹úMayo Clinicת»¯Ò½Ñ§Ñо¿ÖÐÐĺÏ×÷Ñо¿Õß¡£¼æÈÎÖлªÒ½Ñ§»áÐÄѪ¹Ü²¡·Ö»áµÚÊ®½ìίԱ»á½éÈëѧ×éίԱ¡¢ÖлªÔ¤·Àҽѧ»áÂý²¡¿ØÖÆÓëÔ¤·À·Ö»áÇàÄêίԱ»á¸±Ö÷ÈÎίԱ¡¢ÁÉÄþʡϸ°ûÉúÎïѧ»áÐÄѪ¹ÜÄÚ¿ÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á¸±Ö÷ÈÎίԱ¡¢ÖлªÖÐҽҩѧ»á½éÈëÐÄÔಡ·Ö»áίԱ¡¢Öйú½éÈëҽʦѧ»áÐÄѪ¹Ü²¡Ñ§×éίԱ¡¢ÁÉÄþʡҽѧ»áÐÄѪ¹Ü²¡·Ö»áµÚ°Ë½ìίԱ»áίԱµÈѧ»áÈÎÖ°£¬Í¬Ê±µ£ÈΡ¶ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾¡·¡¢¡¶Öлª½¡¿µ¹ÜÀíѧÔÓÖ¾¡·¡¢¡¶ChronicDisease and Translational Medicine¡·¡¢¡¶ÖйúÑ­Ö¤ÐÄѪ¹ÜҽѧÔÓÖ¾¡·¡¢¡¶Öйúϸ°û¹¤³ÌÑо¿¡·µÈÔÓÖ¾±àί»òͨѶ±àί¡£ÒÑÖ÷³ÖÍê³É¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð1Ïî¡¢½ÌÓý²¿¼°ÁÉÄþÊ¡½ÌÓýÌüÏîÄ¿¸÷1ÏĿǰÖ÷³ÖÁÉÄþÊ¡½ÌÓýÌü¿ÎÌâ1Ï´óÁ¬Ò½¿Æ´óѧת»¯Ò½Ñ§»ù½ðÏîÄ¿1Ïî¼°±±¾©Á¦ÉúÐÄѪ¹Ü»ù½ð»áÓÅÐãÏîÄ¿»ù½ð1Ïî¡£×÷ΪÖ÷ÒªÑо¿ÈË£¬Ö÷³Ö×¢²á¶àÖÐÐÄÁÙ´²Ñо¿4ÏÒÑÍê³É1ÏÆäÖÐÔÚÖйúµØÇøÊ״βÉÓÃÁÙ´²¹²Í¬¾ö²ß·½·¨¶ÔÐÄÔಡ»¼Õß¿ªÕ¹ÁÙ´²Ñо¿2Ïî¡£2011ÄêÈëÑ¡ÁÉÄþÊ¡°ÙǧÍòÈ˲żƻ®¡°Ç§È˲ã´Î¡±ºÍ´óÁ¬ÊÐÁì¾üÈ˲źó±¸È˲żƻ®£¬2013ÄêÈëÑ¡´óÁ¬Ò½¿Æ´óѧӢ²Å¹¤³Ìºó±¸È˲ţ¨µÚÒ»²ã´Î£©¡£ÒÑÔÚHeart¡¢European Journal of Heart Failure¡¢Stem Cell Research & TherapyµÈÖÐÓ¢ÎÄÆÚ¿¯·¢±íÏà¹ØѧÊõÂÛÎÄ70Óàƪ£¬ÔøÊÜÑûÔÚÃÀ¹ú½éÈëÐÄÔಡ´ó»á£¨TCT£©¡¢Å·ÖÞÐÄÔಡÄêºó£¨ESC£©¡¢ÑÇÌ«½éÈëÐÄÔಡѧ´ó»á£¨Asia Pacific TCT£©¡¢¹ú¼Êѭ֤ҽѧ´ó»á£¨ISDM£©¡¢ÈÕ±¾½éÈëÐÄÔಡ´ó»á¡¢ÖлªÒ½Ñ§»áÐÄѪ¹Ü²¡Äê»á¡¢¶«·½¹ú¼ÊÐÄÔಡ´ó»á£¨OCC£©¡¢³¤³Ç¹ú¼ÊÐÄÔಡ´ó»áµÈ¹ú¼ÊÖØÒªÐÄѪ¹Ü²¡Ñ§Êõ»áÒéÉÏ¿ÚÍ·±¨¸æ»ò±Ú±¨½»Á÷£¬»ñµÃÓÅÐãÂÛÎĽ±»òÇàÄêҽʦÑо¿½±¡£µ£ÈιúÄÚÖ÷ÒªöλÔÓéÀֵǼÈë¿ÚÏÂÔØѧÊõ»áÒéÈçÖйú½éÈëÐÄÔಡѧ´ó»á£¨CIT£©¡¢ÖйúÐÄÔಡ´ó»á£¨CHC£©¡¢ÖлªÒ½Ñ§»áÐÄѪ¹Ü²¡Äê»á¡¢¶«·½¹ú¼ÊÐÄÔಡ´ó»á£¨OCC£©¡¢³¤³Ç¹ú¼ÊÐÄÔಡ´ó»á¡¢¹ÚÂöÂýÐÔ±ÕÈûÐÔ²¡±ä£¨CTO£©¾ãÀÖ²¿»áÒé¡¢×óÖ÷¸É¼°·Ö²æ²¡±ä´¦ÀíÂÛ̳£¨CBS£©µÈ»áÒéÖ÷ϯÍųÉÔ±£¬Ö÷³Ö¡¢ÌÖÂÛ»òÊÜÑû·¢ÑÔ¡£²ÎÓë±àдרÖø6²¿¡£²ÎÓë»ñµÃÊ¡²¿¼¶¿Æ¼¼½±Àø5Ïî¡£

¿ÆÑй¤×÷ :
ÔÚÑÐÏîÄ¿1. P-Ñ¡Ôñµ°°×ÓëÊ÷ͻ״ϸ°ûÏ໥×÷ÓöԶ¯ÂöÖàÑùÓ²»¯½øÕ¹µÄÓ°Ï죬ÏîÄ¿¸ºÔðÈË£¬2012-2014£¬23Íò£¬¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð£¨**ÒѽáÌ⣩
2. Tenascin-CÔÚ¼±ÐÔÐļ¡¹£ËÀºó¸Éϸ°ûÐÞ¸´ÖÎÁÆÖÐ×÷ÓûúÖÆÑо¿£¬ÏîÄ¿¸ºÔðÈË£¬2015-2017£¬5Íò£¬ÁÉÄþÊ¡×ÔÈ»¿Æѧ»ù½ð£¨**£©
3. ±È½Ï×î¼ÑÒ©ÎïÖÎÁÆ»ù´¡ÉÏ¿ªÍ¨µ¥Ö§CTO²¡±äÓëÒ©ÎïÖÎÁƶԴæ»îÐļ¡µÄÓ°Ï죬ÏîÄ¿¸ºÔðÈË£¬2016-2018£¬´óÁ¬Ò½¿Æ´óѧת»¯Ò½Ñ§ÏîÄ¿Ñо¿»ù½ð
4. ±È½Ï×î¼ÑÒ©ÎïÖÎÁÆ»ù´¡ÉÏ¿ªÍ¨CTOµ¥Ö§²¡±äÓë×î¼ÑÒ©ÎïÖÎÁƶԴæ»îÐļ¡Ó°ÏìµÄÇ°Õ°ÐÔ¡¢¶àÖÐÐÄ¡¢¶ÔÕÕÑо¿£¬ÏîÄ¿¸ºÔðÈË£¬2016-2018, 8Íò£¬±±¾©Á¦Éú»ù½ð»áÁ캽»ù½ðÓÅÐãÏîÄ¿£¨LHJJ**£©
Ö÷³Ö×¢²áÁÙ´²Ñо¿
1. Timing for intracoronary administration of bonemarrow mononuclear cell after acute ST-elevation myocardial infarction£¨ClincalTrial.gov: NCT **£©
2. The success of opening single CTO lesions to improvemyocardial viability study£¨SOS-comdey, ClincalTrial.gov: NCT**£©
3. Change of Serum Tenascin-C Concentration and the RelationshipWith hs-CRP£¬cTnI and Prognosis inPatients With Acute Coronary Syndrome£¨ClincalTrial.gov:NCT**£©
4. Chinese physician¡¯s and patient¡¯s preference forand attitude towards shared decision making (ChiCTR-OCS-**)
´ú±íÐÔÂÛÎÄ£º1£®Ming Tian, Yunchuan Yuan, Jiayi Li, Michale R. Gionfriddo, Rongchong Huang£¨»ÆéÅÁˆ£©.Tumor Necrosis Factor-¦Á and Its Role as a Mediator in Myocardial Infarction: A Brief Review.Chronic Disease andTranslational Medicine, 20151:18-26(ͨѶ×÷Õß)
2£®Ding Huaiyu, Shi Xiaoli, Wu Baolin, Huang Rongchong(»ÆéÅÁˆ). Stress induced cardiomyopathy after infection ofthe upper respiratory tract in an old woman. Experimental and Therapeutic Medicine (article in press) (ͨѶ×÷Õß)
3£®RongchongHuang£¨»ÆéÅÁˆ£©, Kang Yao, Aijun Sun, Juying Qian,Lei Ge, Yiqi Zhang, Yuhong Niu, Keqiang Wang, Yunzeng Zou, Junbo Ge. Timing forintracoronary administration of bone marrow mononuclear cell after acuteST-elevation myocardial infarction. StemCell Research & Therapy, 20156:112-123(29 May, 2015)(µÚÒ»×÷Õß)
4£®RongchongHuang£¨»ÆéÅÁˆ£©, Lizhi Zhang, Michale R. Gionfriddo, Aaron Leppin, Henry H. Ting, VictorM. Montonri. Shareddecision making in China: Current Status and Future Directions. Patient Preference and Adherence. 20159:1129-1141(6 August, 2015)(µÚÒ»×÷ÕߺÍͨѶ×÷Õß)
5£®K Yao *, R Huang £¨»ÆéÅÁˆ£©*, JQian, J Cui, L Ge, Y Li, F Zhang, H Shi,D Huang, S Zhang, A Sun, Y Zou and J Ge. Administrationof intracoronary bone marrow mononuclear cells on chronic myocardial infarctionimproves diastolic function. Heart. 200894(9):1147-1153. (¹²Í¬µÚÒ»×÷Õß)
6£®Kang Yao*, RongchongHuang£¨»ÆéÅÁˆ£©*, Aijun Sun*,Juying Qian, Xuebo Liu, Lei Ge, Yiqi Zhang, Shuning Zhang, Yuhong Niu, QibingWang, Yunzeng Zou ang Junbo Ge. Repeated Autologous Bone Marrow MononuclearCell Therapy in Patients with Large Myocardial Infarction. Eur J HeartFail, 2009£»11(7): 691-8(*¹²Í¬µÚÒ»×÷Õß)
7£®Michale R. Gionfriddo,Aaron Leppin, Juan P Brito, Annie LeBlanc, Kasey R. Boehmer, Megan A Moris,Patricia J Erwin, Larry J Prokop, Glaudia L Zeballos-Palacios, German Melaga, JJamime Miranda, Heidi M McLeod, Rene Rodriguez-Gutierrez, Rongchong Huang,Oscar L Money-Vargas, Mohammad Hassan Murad and Victor M Montonri. A systematicreview of shared decision making interventions in chronic conditions: a reviewprotocol. Systematic Reviews,2014 3: 38-44
8£®Zhang B, Zhang W, Huang R£¨»ÆéÅÁˆ£©, Zhu H, Liu J, Jiang D, Ren L, Zhou X, Qi G. Gender and AgeDifferences Associated With Prehospital Delay in Chinese Patients PresentingWith ST-Elevation Myocardial Infarction. J Cardiovasc Nurs, 2016 Mar-Apr31(2):142-50.2014 Nov 21 [Epub ahead of print]
9£®Zhang B, Shen DP, Zhou XC, Liu J,Huang RC£¨»ÆéÅÁˆ£©,Wang YE, Chen AM, Zhu YR, Zhu H. Long-term prognosis of patients with acutenon-ST-segment elevation myocardial infarction undergoing different treatmentstrategies. Chin Med J (Engl). 2015 Apr 20128(8):1026-31.
10£® Wang SP, Huang RC£¨»ÆéÅÁˆ£©, Zhu H, Zhang B,Zheng ZG, Yin D, Wang JJ, Zhou XC. Safety and efficacy of a non-polymericpaclitaxel-eluting microporous stent in real-world percutaneous coronaryintervention. Exp Ther Med. 2013 Sep6(3):811-815. Epub 2013 Jul 11.11£® Zhang B, Zhang W, Huang RC£¨»ÆéÅÁˆ£©, Zhang Y, Liu J, Zheng ZG, Jiang DM,Sun YJ, Ren LN, Zhou XC, Qi GX. Gender disparity in early death afterST-elevation myocardial infarction. Chin Med J (Engl).**(18):3481-5.12£® Yao K, Lu H, Huang R£¨»ÆéÅÁˆ£©, Zhang S, Hong X, Shi, H, Sun A, QianJ, Zou Y, Ge J. Changes of dendriticcells and fractalkine in type 2 diabetic patients with unstable anginapectoris: a preliminary report. Cardiovasc Diabetol. 2011Jun 1010:50.13£® Zhou XC, Huang RC£¨»ÆéÅÁˆ£©, Zhang B, Yin D, Liang B, Wang SP,Guan QG, Sun XZ, Miao ZL, He XZ, Han FT, Cheng Y, Zhang L, Zeng DY.Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents oninterleukin-1¦Â-induced coronary artery in-stent restenosis in pigs. Chin Med J (Engl), 2010, 123(17):2405-240914£® Shi Hongyu, Ge Junbo, Fang Weiyi, YaoKang, Huang Rongchong£¨»ÆéÅÁˆ£©., et al. Peroxisomeproliferator-activated receptor alpha agonist attenuates oxidized-low densitylipoprotein induced immune maturation of human monocyte-derived dendriticcells. Chin Med J (Engl), 2008 121(17):1747-1750.15£® Shi Hongyu, Ge Junbo, Fang Weiyi, YaoKang, Huang Rongchong£¨»ÆéÅÁˆ£©. Selective Decrease in CirculatingMyeloid Dendritic Cells in Type 2 Diabetic Men with Atherosclerotic CoronaryArtery Disease. Am J Cardiol, 2007 100(4): 593-59716£®»ÆéÅÁˆ. Ó¦ÖØÊÓ¸Éϸ°ûÒÆÖ²ÖÎÁƹÚÐIJ¡µÄ°²È«ÐÔÆÀ¼Û£¨ÊöÆÀ£©. ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾£¬2012£¬40(9):721-72217£®»ÆéÅÁˆ£¬¸ð¾ù²¨.´Ó¸ÄÉÆÖÖ×Óϸ°ûÈëÊÖÌá¸ß¸Éϸ°ûÒÆֲЧÂÊ£¨ÊöÆÀ£©.ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾£¬2009, 37(8):675-67918£®»ÆéÅÁˆ£¬¸ð¾ù²¨.¸Éϸ°ûÒÆÖ²ÖÎÁƹÚÐIJ¡µÄÏÖʵÓëÌôÕ½£¨ÊöÆÀ£©. ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾£¬2008,36(8):673-67419£®»ÆéÅÁˆ£¬¸ð¾ù²¨. ¹ÇËè¸Éϸ°ûÒÆÖ²ÖÎÁƼ±ÐÔÐļ¡¹£ËÀÑо¿ÏÖ×´£¨ÊöÆÀ£©.ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾£¬2007£¬35£¨6£©£º497-820£® Ê·ÏþÀû£¬ÕÔÑÞ»Ô£¬»ÆéÅÁˆ£¬ÇàÄêÄÐÐÔÐļ¡¹£ËÀºóÍâÖÜѪÄÚƤ×æϸ°ûÊýÁ¿±ä»¯Ñо¿£¬ÖйúҽʦÔÓÖ¾£¬2015£»17£¨8£©£º1153-1156£¨Í¨Ñ¶×÷Õߣ©21£® Áº±õ£¬ÆÝÕ棬¶¡»³Óñ£¬ÖÓÀ×£¬Î䱦ÁÖ£¬»ÆéÅÁˆ. BÐÍÀûÄÆëÄÓë¹Ú×´¶¯Âö²¡±ä³Ì¶È¼°ÐŦÄÜÏà¹ØÐÔÑо¿.ÖйúʵÓÃÄÚ¿ÆÔÓÖ¾£¬2015£»35£¨3£©£º257-258£¨Í¨Ñ¶×÷Õߣ©22£® Áº±õ£¬»ÆéÅÁˆ£¬¿µÃÀÀö£¬Ê·ÏþÀû£¬ÀîÖÇ£¬Áõ¿¡£¬Öì𩣬ÖÜÐñ³¿.ÐĵçͼÒÔST¶Î̧¸ßΪÌØÕ÷µÄTakoSTuboÐļ¡²¡Óë¼±ÐÔÇ°±ÚST¶Î̧¸ßÐÔÐļ¡¹£ËÀÁÙ´²ÌØÕ÷±È½ÏÑо¿.ÖйúÑ­»·ÔÓÖ¾£¬2015:30(6): 534-539£¨Í¨Ñ¶×÷Õߣ©23£®Áº±õ£¬³ÂÓ꣬Î䱦ÁÖ£¬¶¡»³Óñ£¬ÖÓÀ×£¬»ÆéÅÁˆ.ÔìÓ°¼Á¼ÁÁ¿¶Ô¹ÚÐIJ¡»¼ÕßPCIÊõºóÉö¹¦ÄܵÄÓ°Ïì. ¹óÑôҽѧԺѧ±¨£¬2015£»40£¨3£©£º532-535£¨Í¨Ñ¶×÷Õߣ©24£®Ð»½¨Î°£¬Öì𩣬»ÆéÅÁˆ.PCIÊõÖжԱȼÁ¼ÁÁ¿Ó뻼ÕßѪ¼¡ôû¡¢ÉöСÇòÂ˹ýÂÊ¡¢¼¡ôûÇå³ýÂʵÄÏà¹ØÐÔ¼°¶Ô½üÖÐÆÚ²»Á¼Ê¼þµÄÓ°Ïì.ÒÉÄѲ¡ÔÓÖ¾£¬2015£»14£¨4£©£º338-34225£®²ÜÐÇ÷£¬ËÎÏÖÌΣ¬»ÆéÅÁˆ£¬C·´Ó¦µ°°×Ö¹Ú×´¶¯Âö¾·ÂÎÑо¿½øÕ¹£¬ÖлªÒ½Ñ§ÔÓÖ¾£¬2015£¬95£¨43£©£º3551-355326£® ¹ù࣬ÕŶ«·ï£¬»ÆéÅÁˆ£¬ËÎÏÖÌΣ¬ÔËÓÃÒ½»¼¹²Í¬¾ö²ßģʽ¸ÄÉƹÚÐIJ¡ÖÎÁÆÏÖ×´£¬ÖйúÑ­Ö¤ÐÄѪ¹ÜҽѧÔÓÖ¾£¬2015£¬7£¨4£©£º572-57427£® ãÆ˧£¬»ÆéÅÁˆ£¬ËÎÏÖÌÎ.½Ñµ°°×-1¶ÔѪ¹ÜÕÅÁ¦µÄÓ°Ïì.ÐÄ·ÎѪ¹Ü²¡ÔÓÖ¾£¬2014£»33£¨6£©:890-89328£® »ÆÁ¢Æ¼£¬»ÆéÅÁˆ. ±äÒìÐÔÐĽÊÍ´»¼Õ߶¯Ì¬ÐĵçͼST¶Î̧¸ßÓë¹Ú×´¶¯Âö²¡±äµÄ¹Øϵ£¬Öйú½éÈëÐÄÔಡѧÔÓÖ¾£¬2012£»20£¨1£©£º13-16£¨Í¨Ñ¶×÷Õߣ©29£® Ê·ÏþÀû£¬ÀîÖÇ£¬ÕÔÑÞ»Ô£¬Öì𩣬Áõ¿¡£¬ÖÜÐñ³¿£¬»ÆéÅÁˆ. ÇàÄê¼±ÐÔÐļ¡¹£ËÀµÄÁÙ´²Ìص㼰Ѫ֬Òì³£Óë½üÖÐÆÚÔ¤ºó¹ØϵµÄÁÙ´²Ñо¿£¬ÁëÄÏÐÄѪ¹Ü²¡ÔÓÖ¾£¬2012 18(4): 412-415£¨Í¨Ñ¶×÷Õߣ©30£® Áº±õ£¬ÖÜÐñ³¿£¬»ÆéÅÁˆµÈ.Á£Ï¸°û¼¯Âä´Ì¼¤Òò×Ó¶ÔȱѪÔÙ¹à×¢ËðÉËÖíÐļ¡µòÍöºÍÐļ¡ÏËά»¯µÄÓ°Ïì. ´óÁ¬Ò½¿Æ´óѧѧ±¨£¬2010, 32(3):237-241£¨Í¨Ñ¶×÷Õߣ©31£® »ÆéÅÁˆ£¬Ò¦¿µ£¬Â½ºÆµÈ. ¾­¹ÚÂöÄÚG-CSF×¢ÉäÖÎÁÆÂýÐÔȱѪÐÔÐÄÔಡµÄʵÑéÑо¿. ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾£¬2009,37(8):685-69132£®»ÆéÅÁˆ£¬Ò¦¿µ£¬Ç®¾ÕÓ¢µÈ. Ë«ºËËØSPECTÆÀ¼Û¹ÇËèµ¥¸öºËϸ°ûÒÆÖ²ºó¼±ÐÔÐļ¡¹£ËÀ»¼Õß´æ»îÐļ¡±ä»¯. ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾£¬2007£¬35£¨6£©£º501-433£® »ÆéÅÁˆ£¬Ò¦¿µ£¬×ÞÔÆÔöµÈ. ¼±Õï¾­¹ÚÂö×ÔÌå¹ÇËèµ¥¸öºËϸ°ûÒÆÖ²ÖÎÁƼ±ÐÔϱÚÐļ¡¹£ËÀ³¤ÆÚËæ·Ã¹Û²ì. ÖлªÒ½Ñ§ÔÓÖ¾£¬2006£¬86£¨16£©£º1107-1110.34£®»ÆéÅÁˆ£¬Ò¦¿µ£¬ÀîÑÓÁÖµÈ. ¾­¹Ú×´¶¯Âö¹ÇËèµ¥¸öºËϸ°ûÒÆÖ²ÖÎÁÆÔ­·¢ÐÔÀ©ÕÅÐÍÐļ¡²¡µÄ°²È«ÐÔÓëÁÆЧ½üÆÚ¹Û²ì. ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾£¬2006£¬34£¨2£©£º111-113.35£®²ÜÐÇ÷, ËÎÏÖÌÎ, »ÆéÅÁˆ, ³ÂÑÇÀÚ, Àõ¼ÑÄÐ. ÌåÍâ¹Ú×´¶¯Âö¾·ÂÎ΢»·¾³Ä£Ð͵Ĺ¹½¨. Öйú·Ö×ÓÐÄÔಡѧÔÓÖ¾. 2015:1511-1515.36£®ÕŲ¨£¬¶­Ü°£¬ÕÅåû£¬»ÆéÅÁˆ£¬Òü´ï£¬Ö£Õñ¹ú£¬ÁõÓñ¹û£¬Öì𩣬ÖÜÐñ³¿. ¼±ÐÔ¹Ú×´¶¯Âö×ÛºÏÕ÷»¼Õß½éÈëÖÎÁƺóµÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼´ï±êÂʼ°Ó°ÏìÒòËØ·ÖÎö.ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾, 2014, 42(4):290-29437£®Ö£Õñ¹ú£¬Öì𩣬Íõ¿¡½Ü£¬ÕŲ¨£¬Òü´ï£¬ÍõÉÙÅô£¬ÕÅåû£¬»ÆéÅÁˆ£¬ÖÜÐñ³¿. ¹Ú×´¶¯Âö°ÐѪ¹ÜШѹ²â¶¨·¨ÆÀ¼ÛST¶Î̧¸ßÐÔÐļ¡¹£ËÀ»¼Õß¹Ú×´¶¯Âö²à֦ѭ»·ÐγɶÔÐļ¡´æ»î³Ì¶ÈµÄÓ°Ïì. Öйúҽʦ½øÐÞÔÓÖ¾£¬2013,36£¨31£©£º15-18.38£®ÕŲ¨£¬»ÆéÅÁˆ£¬Òü´ï£¬ÕÅåû£¬Öì𩣬Áõ¿¡£¬ÖÜÐñ³¿¡£ST¶Î̧¸ßÐļ¡¹£ËÀ»¼ÕßÕïÁÆ×´¿ö¼°Ô¤ºóµÄµ¥ÖÐÐÄÑо¿. ´óÁ¬Ò½¿Æ´óѧѧ±¨£¬2011,33:462-465.39£®ÒüÏþÃË£¬»ÆéÅÁˆ£¬ÏÄÔÆÁú£¬ÍõÓ¨çù£¬´ÔÌΣ¬¸ßÁ¬¾ü£¬ÕÅÊ÷Áú£¬»ÆÁ¢Æ¼£¬ÁÖÖκþ£¬ÑîÑÓ×Ú¡£Ë«Ç»Æð²«Æ÷Êõºó·¿ÊÒ¼ä¸ôµÄ³Ì¿Ø¹ÜÀí£¬ÖйúÁÙ´²Ò½Ñ§£¬2011£¬18£¨1£©:40£®ÑîÜø£¬×ÞÔÆÔö£¬Ñîɺ£¬»ÆéÅÁˆ£¬Ò¦¿µ£¬ÀîÑÓÁÖ£¬¸ð¾ù²¨¡£×ÔÌå¹ÇËè¸Éϸ°ûÒÆÖ²ºÍÁ£Ï¸°û¼¯Âä´Ì¼¤Òò×Ó¶¯Ô±×ÔÌå¹ÇËè¸Éϸ°ûÖÎÁƼ±ÐÔÐļ¡¹£ËÀµÄÁÆЧ±È½Ï£¬ÖйúҽѧǰÑØÔÓÖ¾£¨µç×Ӱ棩£¬2011£¬3£¨4£©£º58-6141£®ÍõÓÀ¾ü£¬ÖÜÐñ³¿£¬»ÆéÅÁˆ£¬ÕÅåû£¬ÓàÔÚϼ£¬ÕÔ¾ü¿ý£¬Ê¯Ó£¬Âí°®Èï¡£¾­½éÈëÖÎÁÆÅ®ÐÔ¹ÚÐIJ¡»¼ÕßÊõǰѪ֬ˮƽ·ÖÎö¼°ÓëSyntaxÆÀ·ÖµÄ¹Øϵ£¬ºÓ±±Ò½Ò©£¬2011£¬1942£®ÍõÓÀ¾ü£¬ÖÜÐñ³¿£¬»ÆéÅÁˆ£¬ÕÅåû£¬ÓàÔÚϼ£¬ÕÔ¾ü¿ý£¬Ê¯Ó£¬Âí°®ÈŮÐÔ¹ÚÐIJ¡ÁÙ´²ÌØÕ÷Óë¹Ú×´¶¯Âö²¡±äÌصã·ÖÎö£¬ºÓ±±Ò½Ò©£¬2011£¬1643£®Òü´ï£¬Öì𩣬ÖÜÐñ³¿£¬»ÆéÅÁˆ£¬ÕŲ¨£¬ÍõÉÙÅô£¬ÕÅÓÓÉú£¬¼ÖÓñÇ䣬ËïÃκ­£¬´Þ¹þÉꡣѪ˨³éÎüÁªºÏ¹ÚÂöÄÚÌæÂÞ·Ç°à×¢Éä¶ÔÐļ¡ÔÙ¹à×¢µÄÓ°Ï죬½éÈë·ÅÉäѧÔÓÖ¾£¬2011£¬744£®ÍõÚSÚS£¬»ÆéÅÁˆ£¬ÖÜÐñ³¿µÈ. ÏÙÜÕ¸ººÉÐļ¡ºËËØÏÔÏñÆÀ¼ÛÂýÐÔÍêÈ«±ÕÈû²¡±ä´æ»îÐļ¡µÄÁÙ´²Ñо¿. Öйú½éÈëÐÄÔಡѧÔÓÖ¾£¬2010,18£¨5£©£º257-26145£®Ò¦Ö¾·å£¬»ÆÕãÓ£¬½âÐÂÐÇ£¬ÕÅÊéÄþ£¬¹®Ñ©£¬Ñîɺ£¬ÕÅÉٺ⣬»ÆéÅÁˆ£¬½ðº½£¬ÔøÃÉËÕ£¬Ëï°®¾ü£¬×ÞÔÆÔö£¬¸ð¾ù²¨¡£Öí¹ÇËè¼ä³äÖʸÉϸ°û³¬Ë³´ÅÐÔÑõ»¯Ìú±ê¼Ç·½·¨µÄʵÑéÑо¿£¬ÖйúÁÙ´²Ò½Ñ§£¬2009£¬16£¨5£©46£®¸ðÀ×£¬Âí½¨Ó¢£¬ÇØÇ磬½ºÆ£¬Ò¦¿µ£¬»ÆéÅÁˆ£¬»ÆÕãÓ£¬Õŷ壬Áõѧ²¨£¬Íõå°£¬Ç®¾ÕÓ¢£¬¸ð¾ù²¨¡£Öйú¹Ú×´¶¯ÂöÂýÐÔ±ÕÈû²¡±ä½éÈëÖÎÁÆÏÖ×´³õ²½µ÷²é£¬ÉϺ£Ò½Ñ§£¬2009£¬32£¨12£©47£®ÕŲ¨,»ÆéÅÁˆ, Áº±õµÈ. ¾ø¾­Ç°ºóÅ®ÐÔ¹Ú×´¶¯Âö²¡±ä»¼ÕßÁÙ´²¼°¹ÚÂö²¡±äÌصã.´óÁ¬Ò½¿Æ´óѧѧ±¨£¬2009£¬31(2): 170-172